2010•Guide of China MedicineRequires access
Three Dimensional Conformal Hypofractionated High Dose Radiotherapy Combined with Gemcitabine Concurrent Chemotherapy for Early-stage Non-Small-Cell Lung Cancer
Junqing Han
Open publisher page 0 citations
Abstract
Objective To evaluate the efficacy and toxicity of three dimensional conformal hypofractionated high dose radiotherapy combined with Gemcitabine concurrent chemotherapy for early-stage non-small-cell lung cancer. Methods 28 cases patients with early-stage non-small-cell lung cancer were treated by three dimensional conformal hypofractionated high dose radiotherapy at the total dose of 48 to 54 Gy , 6 to 8 Gy for each fraction, 3 f/w. And they were also given Gemcitabine concurrent chemotherapy: Gemcitabine 600mg/m2, d1, 8. Results The complete remission rate was 39.3% and partial remission rate was 60.7%.The overall response rate was 100%. The 1-, 2-, 3-year survival rates were 96.4%, 78.6% and 71.4%. Conclusion Three dimensional conformal hypofractionated high dose radiotherapy combined with Gemcitabine concurrent chemotherapy for early-stage non-small-cell lung cancer is effective, the survival rate can be improved, the side effects are tolerable. It is one of safe and effective treatment.